At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 391 enrolled
Drug / intervention
SUNPG1623 I +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis
In Brief
A Phase 2 clinical trial evaluating SUNPG1623 I, SUNPG1623 II, and 3 other interventions for Active Psoriatic Arthritis. Completed, enrolled 391 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActive Psoriatic Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartApr 2017
Primary CompletionMar 2019
Study CompletionSep 2019
TodayJul 2026
First PostedDec 2, 2016
Enrollment StartApr 19, 2017
Primary CompletionMar 1, 2019
Study CompletionSep 24, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.6 years ago
Interventions
SUNPG1623 Idrug
injection
SUNPG1623 IIdrug
injection
SUNPG1623 IIIdrug
injection
SUNPG1623 IVdrug
injection
PLACEBOdrug
injection